Alternatives to Germany – Health services – Implementierung telemedizinischer Behandlungen in den niedersächsischen Justizvollzugseinrichtungen

Germany – Vocational rehabilitation services – REZ SW UB AA Stuttgart

Germany – Pharmaceutical products – 61. Generika-Ausschreibung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Irbesartan und Hydrochlorothiazid (ATC: C09DA24)

Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-03

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Vilanterol und Umeclidiniumbromid (ATC: R03AL03)

Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-08

Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Entecavir (ATC: J05AF10 - in der Darreichungsform Filmtabletten)

Expected Outcome: Project results are expected to contribute to all the following expected outcomes: Advance in the achievement of the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy; Efficient and effective support to wind energy research and innovation through alignment and cooperation among different actors, avoiding fragmentation of efforts; Energy producers and consumers benefit from increased performance of wind energy technologies with the focus on efficiency and flexibility, reduced cost, improved reliability and sustainability, operation and maintenance, safety, robustness and security during all stages of the lifetime of a wind energy farm from installation, operation and maintenance to decommissioning; Increased contribution of wind energy to the energy system, with minimal impacts on health and the environment (notably biodiversity and pollution) and at the lowest possible cost. Scope: The action contributes to address the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy, as defined by the Implementation Working Group (IWG) on wind energy, the European…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Researchers of different disciplines use advanced multiscale Virtual Human Twins (VHTs) to expand the knowledge and understanding of cancer onset and progression Healthcare professionals and researchers have access to advanced VHT-based solutions that model cancer onset and progression over time, contributing to improve personalised treatments Researchers, healthcare professionals, innovators and citizens have access to cancer VHTs through the UNCAN.eu and the advanced Virtual Human Twin platforms Scope: Virtual human twins (VHTs) are digital representations and in-silico models of an individual’s health and disease at different levels of the human anatomy (e.g. cells, tissues, organs or organ systems) for the prevention, prediction, screening, diagnosis and treatment of a disease, as well as the selection and personalisation of intervention options [1] . The proposed topic will contribute to the EU Cancer Mission objectives by improving the accuracy of dynamic and multiscale VHTs to better understand cancer…